Antibodies Archives

News and Trends 26 Feb 2016

A New Super-Antibody against Ebola has been Isolated

Humabs BioMed (Switzerland), in collaboration with institutional partners has succeeded in isolating new antibodies against the Ebola virus and turned them into a potential therapy against it. Humabs discovers monoclonal antibodies by doing blood analysis of survivors to given infectious diseases. For example, if one wants the cure for the flu, it looks into people […]

February 26, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 22 Feb 2016

Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?

UCB (Belgium) has a monoclonal antibody candidate (romozumab) which has met its primary endpoints for a phase III Osteoporosis trial, FRAME in partnership with Amgen. The drug showed 75% improvement (compared to placebo) and few side effects. UCB in Brussels is developing immunotherapies for a range of chronic diseases, which has now gotten good phase III results for an […]

February 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 12 Feb 2016

Biotech of the week: Nordic Nanovector & its ARC technology

This week we say ‘au revoir’ to Nantes and head back up to the Scandinavian country that is Norway, in particular it’s capital city, Oslo – the location of our biotech of the week, Nordic Nanovector. City: Oslo, Norway Founded: 2009 Employees: +/- 30 (as off 11/15) Financial Data: €156M Market Cap (on 23/11/2015) CEO: Missions: Betalutin, a potential new treatment […]

February 12, 2016 - 1 minutemin - By Philip Hemme

News and Trends 3 Feb 2016

When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease

ArGEN-X in Ghent (Belgium) combines the diversity of the llama immune system with a clinical antibody pipeline which Leo Pharma (Denmark), is developing to treat inflammatory skin conditions. These llama mAb platforms allow arGEN-X to unlock novel and complex targets and develop antibody-based drugs designed for longer duration of effect and greater efficacy. This is a similar approach to which Ablynx […]

February 3, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 27 Jan 2016

New UK Joint Venture Bridges Gap between Top Universities and Big Pharmas

AstraZeneca, GlaxoSmithKline, Johnson & Johnson and the 3 world-leading universities (Imperial College London, University College London and the University of Cambridge) have joined forces to found the ‘Apollo’ Bridge. This pioneering new joint venture, the Apollo Therapeutics Fund, will support the translation of ground-breaking academic science from within these universities into innovative new medicines for […]

January 27, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Jan 2016

Biotech of the week: Glycotope, the Biggest Biotech in Berlin

After the Christmas and New Year, we continue our journey across Europe to have a glimpse of it’s vast number of Biotechs. This week, we leave Finland behind and head South-West across the Baltic Sea and back to our home town, Berlin, to visit our biotech of the week, Glycotope. City: Berlin, Germany Founded: 2001 Employees: 200 (as of […]

January 8, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 16 Dec 2015

Ovarian Cancer Kills 50,000 Every Year. Now a French Biotech has Bagged €15M to Fight it.

GamaMabs from France (Paris & Toulouse) has secured a €15M Series B Fundraising round for its Antibody targeting Gynecological cancers. GamaMabs Pharma is a French biotechnology company developing innovative monoclonal antibodies in cancer. GamaMabs’ lead project is the monoclonal antibody (mAb) GM102 (formerly known as 3C23K), and they have previously partnered with Curie Cancer Institute […]

December 16, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 4 Dec 2015

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

This week we leave the old city of Oxford and travel South East across the channel, through France and arrive at our destination, Zurich, Switzerland. This wonderful city is famous for its many churches (including the Minster), the largest church clock in Europe, found on St Peter’s and is the home of many celebrities including […]

December 4, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 1 Dec 2015

How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies

Blincyto (Blinatumomab) is the first bispecific antibody construct from Amgen’s BiTE proprietary platform to be granted clinical and regulatory validation so far… After the acquisition in 2012 of Micromet, the Munich-based company that first developed Blinatumomab, Amgen kept revealing the potential of this powerful protein… Blincyto was then approved by the FDA as an orphan […]

December 1, 2015 - 3 minutesmins - By Eva Cosson

News and Trends 26 Nov 2015

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Ablynx – the Belgian Nanobody biotech (which uses monoclonal antibodies of Alpacas) has entered a new and exclusive partnership with the Danish Novo Nordisk on a mysterious disease… Ablynx are famously well connected in the biotech industry, with many huge pharmas licensing out their Alpaca-nanobody tech. Partnerships include AbbVie (Immunology), Boehringer Ingelheim, Genzyme (Multiple Sclerosis/CNS), […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 25 Nov 2015

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Novartis is hitting back in the Biosimilar battleground: now Neulasta, the white blood cell booster for Cancer, is the latest of Amgen’s victims… Neulasta (pegfilgrastim) has been submitted through Novartis’ subsidiary, Sandoz. As a recombinant human granulocyte colony-stimulating factor (G-CSF), pegfilgrastim looks to stimulate the immune system and boost the white cell count. Neulasta is […]

November 25, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 24 Nov 2015

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

The World Leader in the Immuno-Oncology field has teamed up with a major German Investor to better identify breakthrough investment opportunities across the EU. Bristol-Myers Squibb (BMS) has partnered with Life Sciences Partners in Munich to highlight novel immuno-oncology technologies which could be the next blockbusters in the field. Together the two have conspired a […]

November 24, 2015 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Antibodies

A New Super-Antibody against Ebola has been Isolated

Can this Positive Phase III Immunotherapy End Spinal Fractures due to Osteoporosis?

Biotech of the week: Nordic Nanovector & its ARC technology

When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease

New UK Joint Venture Bridges Gap between Top Universities and Big Pharmas

Biotech of the week: Glycotope, the Biggest Biotech in Berlin

Ovarian Cancer Kills 50,000 Every Year. Now a French Biotech has Bagged €15M to Fight it.

Delenex Therapeutics, the Swiss Biotech developing new types of Therapeutic Antibodies

How a Breakthrough Leukemia Drug is Shaping the Future of Bispecific T-Cell Therapies

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!